Difference between revisions of "Motzer RJ, et al. N. Engl. J. Med. (2019) cited as Ref 639 in DOI: 10.1038/s41392-020-0110-5 (Q9902)"

From Wikibase.slis.ua.edu
Jump to navigation Jump to search
(‎Created claim: First Author string (P149): Motzer RJ, #quickstatements; #temporary_batch_1589996169159)
(‎Created claim: Page(s) (P105): 1103-1115, #quickstatements; #temporary_batch_1590074839150)
 
(6 intermediate revisions by the same user not shown)
Property / DOI Identifier
 +
Property / DOI Identifier: 10.1056/NEJMoa1816047 / rank
 +
Normal rank
Property / PubMed ID
 +
Property / PubMed ID: 30779531 / rank
 +
Normal rank
Property / Publication Date
 +
2019
Timestamp+2019-01-01T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 year
Before0
After0
Property / Publication Date: 2019 / rank
 +
Normal rank
Property / Published In Name String
 +
N. Engl. J. Med.
Property / Published In Name String: N. Engl. J. Med. / rank
 +
Normal rank
Property / Volume
 +
380
Property / Volume: 380 / rank
 +
Normal rank
Property / title
 +
Avelumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma (English)
Property / title: Avelumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma (English) / rank
 +
Normal rank
Property / Page(s)
 +
1103-1115
Property / Page(s): 1103-1115 / rank
 +
Normal rank

Latest revision as of 15:47, 21 May 2020

Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
Language Label Description Also known as
English
Motzer RJ, et al. N. Engl. J. Med. (2019) cited as Ref 639 in DOI: 10.1038/s41392-020-0110-5
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8

    Statements

    Motzer RJ
    0 references
    0 references
    2019
    0 references
    N. Engl. J. Med.
    0 references
    380
    0 references
    Avelumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma (English)
    0 references
    1103-1115
    0 references